Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 4, 2022

Chinook Therapeutics Announces Appointment of Charlotte Jones-Burton, M.D., M.S. as Senior Vice President of Product Development and Strategy

GlobeNewswire January 24, 2022

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire January 4, 2022

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy

GlobeNewswire December 14, 2021

Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China

GlobeNewswire November 30, 2021

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 17, 2021

Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 15, 2021

Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering

GlobeNewswire November 9, 2021

Chinook Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 8, 2021

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 8, 2021

Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021

GlobeNewswire November 4, 2021

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021

GlobeNewswire October 15, 2021

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 20, 2021

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire August 12, 2021

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021

GlobeNewswire July 12, 2021

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 7, 2021

Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer

GlobeNewswire June 9, 2021

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

GlobeNewswire June 8, 2021

Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress

GlobeNewswire May 25, 2021